EICHORPublic-registry site landscape for NCT07675824, “REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension”, a Primary Open Angle Glaucoma (POAG) study sponsored by Regeneron Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07675824 (registry record) |
| Study title | REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension |
| Official title | A Phase 1/2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular Hypertension |
| Sponsor | Regeneron Pharmaceuticals |
| Condition(s) | Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OHT) |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 0 |
| Intervention(s) | REGN22530 |
Patient-friendly overview of this study: eichor.com/study/NCT07675824.
Eichor generates a preliminary site-risk snapshot for NCT07675824 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Primary Open Angle Glaucoma (POAG) trials
More from Regeneron Pharmaceuticals
← Eichor home · All tracked trials · Primary Open Angle Glaucoma (POAG) studies · Weekly briefs
